KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Shares Repurchased (2019 - 2025)

Halozyme Therapeutics (HALO) has disclosed Shares Repurchased for 7 consecutive years, with $38.9 million as the latest value for Q3 2025.

  • Quarterly Shares Repurchased changed N/A to $38.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $288.9 million through Dec 2025, up 15.55% year-over-year, with the annual reading at $342.4 million for FY2025, 36.95% up from the prior year.
  • Shares Repurchased for Q3 2025 was $38.9 million at Halozyme Therapeutics, down from $250.0 million in the prior quarter.
  • The five-year high for Shares Repurchased was $252.3 million in Q4 2023, with the low at $1000.0 in Q4 2022.
  • Average Shares Repurchased over 5 years is $114.6 million, with a median of $76.2 million recorded in 2021.
  • The sharpest move saw Shares Repurchased tumbled 100.0% in 2022, then skyrocketed 25229900.0% in 2023.
  • Over 5 years, Shares Repurchased stood at $150.0 million in 2021, then crashed by 100.0% to $1000.0 in 2022, then surged by 25229900.0% to $252.3 million in 2023, then dropped by 0.91% to $250.0 million in 2024, then plummeted by 84.45% to $38.9 million in 2025.
  • According to Business Quant data, Shares Repurchased over the past three periods came in at $38.9 million, $250.0 million, and $252.3 million for Q3 2025, Q4 2024, and Q4 2023 respectively.